Interferon does not prolong progression-free survival after ProMACE-MOPP [5] (multiple letters)

F. Cabanillas, R. I. Fisher, M. Leblanc, Thomas P Miller

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)3322
Number of pages1
JournalJournal of Clinical Oncology
Volume18
Issue number18
StatePublished - Sep 15 2000
Externally publishedYes

Fingerprint

Antineoplastic Combined Chemotherapy Protocols
Procarbazine
Mechlorethamine
Phase III Clinical Trials
Vincristine
Etoposide
Prednisone
Interferon-alpha
Methotrexate
Non-Hodgkin's Lymphoma
Doxorubicin
Cyclophosphamide
Interferons
Disease-Free Survival
Randomized Controlled Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Interferon does not prolong progression-free survival after ProMACE-MOPP [5] (multiple letters). / Cabanillas, F.; Fisher, R. I.; Leblanc, M.; Miller, Thomas P.

In: Journal of Clinical Oncology, Vol. 18, No. 18, 15.09.2000, p. 3322.

Research output: Contribution to journalArticle

@article{753576f0323b4afcab33f6c8c6ae98a8,
title = "Interferon does not prolong progression-free survival after ProMACE-MOPP [5] (multiple letters)",
author = "F. Cabanillas and Fisher, {R. I.} and M. Leblanc and Miller, {Thomas P}",
year = "2000",
month = "9",
day = "15",
language = "English (US)",
volume = "18",
pages = "3322",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - Interferon does not prolong progression-free survival after ProMACE-MOPP [5] (multiple letters)

AU - Cabanillas, F.

AU - Fisher, R. I.

AU - Leblanc, M.

AU - Miller, Thomas P

PY - 2000/9/15

Y1 - 2000/9/15

UR - http://www.scopus.com/inward/record.url?scp=0034666032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034666032&partnerID=8YFLogxK

M3 - Article

C2 - 10986069

AN - SCOPUS:0034666032

VL - 18

SP - 3322

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -